Skip to content

Non Alcoholic Steatohepatitis in Relation to Visceral and Subcutaneous Fat

Non Alcoholic Steatohepatitis in Relation to Visceral and Subcutaneous Fat

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04240145
Enrollment
35
Registered
2020-01-27
Start date
2020-02-01
Completion date
2021-07-30
Last updated
2020-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NASH - Nonalcoholic Steatohepatitis

Brief summary

Evaluate the relationship between the severity of fatty liver in NAFLD assessed by ultrasonography and CT and the visceral fat area measured by CT

Detailed description

Non alcoholic fatty liver disease is one of the most common causes of chronic liver disease world wide . Severe forms of NAFLD such as nonalcoholic steatohepatitis can progress to end-stage liver disease such as cirrhosis or hepatocellular carcinoma. Therefore, investigating risk factors associated with hepatic steatosis is required to perform effective screening . Hepatic steatosis develops for a variety reasons but obesity is the most common associated condition. Obesity is considered a gateway disease and NAFLD is considered to be one of the phenotypes of metabolic syndrome, which is characterized by obesity with visceral fat accumulation, diabetes, hypertension and dyslipidemia. Individuals with severe obesity have a disproportionately high risk of comorbidities including nonalcoholic fatty liver disease (NAFLD), cardiovascular disease and diabetes. The distribution of fat appears more important than the total fat mass in obesity .A predominantly upper body fat distribution increases the risks for the metabolic complications of obesity including hepatic steatosis especially when it is associated with increased intra abdominal fat . Most metabolically obese normal weight subjects have some increase in adipose tissue mass and insulin resistance probably due to an increase in visceral fat. Thus, subjects with a relatively low BMI can have gross increases in abdominal visceral fat, and others with a high BMI may have very little intra abdominal/visceral fat . Several studies suggested visceral adiposity to be a clinical predictor of hepatic steatosis . In addition, the severity of fatty liver has been linked to the VAT area as evaluated by CT.

Interventions

DEVICEMSCT Abdomen

Visceral fat volumetry using MSCT and it's relation to NASH

Sponsors

Gehad Abd Elaziz Mhmoud Ahmad
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years

Inclusion criteria

* patient aged from 18years to 75years of both gender presented to Alrajhi hospital with raised liver enzymes in period from October 2019 to June 2020

Exclusion criteria

* patient with viral hepatitis History of drug intake Auto immune hepatitis

Design outcomes

Primary

MeasureTime frameDescription
NasH in relation to visceral and subcutaneous fatbase lineVisceral fat volumetryusing MSCT and it'srelation tovisceral andsubcutaneous fat

Contacts

Primary ContactGehad Abd Elaziz Mhmoud
gehadabdelazia@yahoo.com01005304239

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026